Pharmacia & Upjohn Co. LLC

Primary objective: Compare the efficacy of Elranatamab with that of Lenalidomide Key secondary objectives: Compare the efficacy of Elranatamab with that of Lenalidomide Secondary objectives: Compare the efficacy of Elranatamab with that of Lenalidomide; Determine the safety and tolerability of Elranatamab; Evaluate the pharmacokinetics of Elranatamab; Evaluate the immunogenicity of Elranatamab; Evaluate the effect of the study treatment intervention on the HRQoL of the subjects. Tertiary/exploratory objectives: Explore the relationship between Elranatamab and the biology of MM in the subjects; Explore the association between Elranatamab exposure and efficacy, safety, and biomarker endpoints, if data permit; Evaluate the effect of the study treatment intervention on patient-reported symptoms and function; Collect healthcare resource utilization data.

Primary study objective: To compare the efficacy of Elranatamab (Arm A) with Daratumumab + Pomalidomide + Dexamethasone (Arm C) by PFS measurement. Secondary study objectives: 1. To compare the efficacy of Arm A with Arm C by OS measurement 2. To compare the efficacy of Arm A with Arm C by measuring PFS, PFS2, ORR, DOR, CRR, DOCR, TTR, % MRD-negative and % sustained MRD-negative 3. To determine the safety and tolerability of Elranatamab monotherapy 4. To evaluate the PK of Elranatamab 5. To evaluate the immunogenicity of Elranatamab 6. To evaluate the effect of treatment on the HRQoL of subjects in Arm A and Arm C

To evaluate the efficacy of once-daily (QD) crisaborole as long-term topical maintenance therapy in reducing relapses in patients who responded to twice-daily (BID) crisaborole.